CFAP20

Across TCGA pan-cancer cohorts, CFAP20 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CFAP20 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CFAP20 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CFAP20 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

STAD are the cancer types where CFAP20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	1.000	0.337	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

CFAP20–STAD (DFS)

Open the STAD breakdown →